Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma

Authors

Brian T. Hill, Taussig Cancer Center
Zachary J. Roberts, a Gilead Company
Allen Xue, a Gilead Company
John M. Rossi, a Gilead Company
Mitchell R. Smith, Taussig Cancer Center

Document Type

Letter to the Editor

Publication Date

6-1-2020

Journal

Bone Marrow Transplantation

Volume

55

Issue

6

DOI

10.1038/s41409-019-0657-3

APA Citation

Hill, B., Roberts, Z., Xue, A., Rossi, J., & Smith, M. (2020). Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma. Bone Marrow Transplantation, 55 (6). http://dx.doi.org/10.1038/s41409-019-0657-3